Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

Krystal Biotech (NASDAQ: KRYS) will report first quarter 2026 financial results on Monday, May 4, 2026, released prior to the open of U.S. markets.

Rhea-AI Summary

Krystal Biotech (NASDAQ: KRYS) will report first quarter 2026 financial results on Monday, May 4, 2026, released prior to the open of U.S. markets.

Management will host a conference call and webcast at 8:30 AM ET on May 4, 2026 to discuss results and provide a business update. A replay will be available for at least 30 days on the company investor website.

Argus Apr 21 session

-1.39% close to close Open Argus

Details

News Market Reaction – KRYS

On Apr 21, the day this news came out, KRYS closed 1.39% below the previous close.

Data tracked by StockTitan Argus for the Apr 21 session.

Market Context

This announcement schedules Krystal Biotech’s Q1 2026 earnings release and webcast, continuing its p...

Analysis

This announcement schedules Krystal Biotech’s Q1 2026 earnings release and webcast, continuing its pattern of pre-announcing reporting dates and access details. Historically, a similar earnings-date notice led to only a modest -0.7% move, suggesting these updates are largely procedural. In evaluating upcoming results, investors may focus on VYJUVEK revenue growth, pipeline progress highlighted in recent filings, and how cash and spending trends compare to prior guidance.

Key Figures

Earnings release date: May 4, 2026 Conference call time: 8:30 am ET Cumulative net product revenue: $730.3 million +5 more

Earnings release date

May 4, 2026

Q1 2026 financial results report date

Conference call time

8:30 am ET

Q1 2026 earnings call start time

Cumulative net product revenue

$730.3 million

Since U.S. launch of VYJUVEK per ARS filing

Non-affiliate market value

$3.5 billion

Aggregate value of common stock held by non-affiliates as of Jun 30, 2025

Shares outstanding

29,232,189

Common shares outstanding as of Feb 11, 2026

CEO sale size

25,000 shares

Open-market sales on March 4, 2026 under Rule 10b5-1 plan

Current share price

$276.50

Price prior to Q1 2026 earnings-date announcement

52-week range

$122.80–$298.30

52-week low and high before this news

Previous Earnings date Reports

1 past event · Latest: Feb 10

Same Type 1 event

1. Feb 10

   Earnings date notice

   24h Move

   -0.7%

   Set reporting date and webcast details for Q4 and FY2025 results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May 4, 2026, prior to the open of U.S. markets.

The Company’s management will also host a conference call and webcast at 8:30 am ET on Monday, May 4, 2026, to discuss the financial results and provide a business update.

Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53916.

For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company’s website at www.krystalbio.com.

About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK^®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).

CONTACT
Investors and Media:                                                             
Stéphane Paquette, PhD
Krystal Biotech
spaquette@krystalbio.com                                    

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Krystal Biotech (KRYS) report Q1 2026 results and what is the release timing?

Krystal Biotech will report Q1 2026 results on May 4, 2026, released before U.S. markets open. According to Krystal Biotech, the company will publish results prior to the market open, allowing investors time to review before trading begins.

What time is the Krystal Biotech (KRYS) earnings conference call and webcast on May 4, 2026?

The conference call and webcast are scheduled for 8:30 AM ET on May 4, 2026. According to Krystal Biotech, management will discuss the quarter and provide a business update during the live webcast and call.

How can investors access Krystal Biotech (KRYS) live webcast and where is the replay posted?

Investors can access the live webcast via the company webcast link and investor website. According to Krystal Biotech, a replay will be available for at least 30 days on the Investors section of the company website.

Will a replay of the Krystal Biotech (KRYS) May 4, 2026 webcast be available if I miss the live call?

Yes. A replay will be available for at least 30 days after the live event. According to Krystal Biotech, the replay will be posted on the company investor website for on-demand access by investors and the public.

What should shareholders expect from Krystal Biotech's (KRYS) May 4, 2026 business update?

Shareholders should expect management commentary on Q1 2026 results and ongoing business activities during the call. According to Krystal Biotech, the webcast will cover financial results plus a business update, offering context for the quarter and near-term priorities.